SOURCE: BioTech Medics, Inc.

November 16, 2007 09:25 ET

BioTech Medics, Inc. Announces Reverse Stock Split and Symbol Change

DALLAS, TX--(Marketwire - November 16, 2007) - BioTech Medics, Inc. [formerly (PINKSHEETS: BTME), now (PINKSHEETS: BMCS)] announces the notice from NASDAQ according to The Exchange Act Rule 10b-17 to approve a reverse stock split and symbol change from BTME to BMCS effective at the open of the stock market today.

On October 25, 2007, pursuant to Section 78.320 of the Nevada Revised Statutes, a majority of shareholders of BioTech Medics, Inc. consented to amend the Articles of Incorporation to a 1 for 20 reverse stock split for the outstanding shares of common stock. As a result of the stock split, each twenty (20) shares of common stock issued and outstanding before the effectiveness of the split shall be exchanged for one (1) share of common stock after the split. No small shareholders will be cashed out. Fractional shares will be rounded up to the next whole share. The Amendment was filed with the Nevada Secretary of State on Nov. 5, 2007. The outstanding shares (o/s) will be approximately 8.09 million at the open of today's market. The authorized shares remain at 500 million, there are no preferred shares issues.

Shareholders will not be required to return their old stock certificates for new certificates; however, shareholders may voluntarily exchange their BTME shares for BMCS shares for a fee charged by Transfer Online. Their web site is www.transferonline.com.

The Board of Directors together with a majority of shareholders voted on the reverse stock split to better achieve the business purposes of the Company and to increase the price of the stock to attract investors.

BioTech Medics is a ten-year-old company and owns, operates and affiliates with Pain Management & Wellness Centers that have non-hazardous high-powered therapeutic medical Class IIIB lasers that are used for the reduction of acute and chronic muscular, skeletal and/or arthritic pain. Conditions such as back pain, arthritis, carpal tunnel, joint and nerve pain, sports injuries, accidents and work-related injuries can be treated easily and non-surgically in clinical sessions lasting less than 30 minutes in one of BioTech's Pain Management & Well Centers.

BioTech is the patent holder of SHBAN™ Hand Sanitizer which is an anti-microbial clinically proven to kill Staph and the Avian Bird Flu Virus together with most common germs, fungus and bacteria. SHBAN is superior to other hand sanitizers because SHBAN has no alcohol, is non-toxic (when used as directed) and leaves an invisible protective film on your hands for long-lasting protection.

Safe Harbor for Forward-Looking Statements

This release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. The FDA has made no evaluation of SHBAN. SHBAN is not made to diagnose, cure or treat any disease.

Contact Information

  • Contact:
    Investor Relations
    1-972-274-5533